Shukra Pharmaceuticals Limited (BOM:524632)
India · Delayed Price · Currency is INR 31.71
-0.01 (-0.03%)
At close: Jul 27, 2026
Shukra Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 59.76 | 121.18 | 99.8 | 39.73 | 2.9 |
Cash & Short-Term Investments | 59.76 | 121.18 | 99.8 | 39.73 | 2.9 |
Cash Growth | -50.68% | 21.41% | 151.21% | 1271.89% | -42.59% |
Accounts Receivable | 229.48 | 87.67 | 245.13 | 301.87 | 74.01 |
Other Receivables | - | 193.25 | 64.67 | 82.3 | - |
Receivables | 251.79 | 383.22 | 329.59 | 406.95 | 99.5 |
Inventory | 139.03 | 99.53 | 23.14 | 31.57 | 39.54 |
Prepaid Expenses | - | 0.11 | 0.17 | 0.22 | 0.59 |
Other Current Assets | 387.52 | 50.24 | 109.62 | 52.25 | 16.2 |
Total Current Assets | 838.1 | 654.27 | 562.33 | 530.72 | 158.72 |
Property, Plant & Equipment | 336.3 | 213.43 | 216.05 | 218.95 | 192.41 |
Total Assets | 1,174 | 867.7 | 778.37 | 749.66 | 351.13 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 100.65 | 92.16 | 72.21 | 336.22 | 85.9 |
Accrued Expenses | - | 15.37 | 10.81 | 9.18 | 10.33 |
Current Portion of Long-Term Debt | 18.27 | 10.64 | 4.97 | 13.13 | 2.5 |
Current Unearned Revenue | - | 26.44 | 35.28 | 66.12 | 24.68 |
Other Current Liabilities | 112.01 | 28.22 | 18.25 | 0.42 | 0.36 |
Total Current Liabilities | 230.92 | 172.84 | 141.53 | 425.06 | 123.77 |
Long-Term Debt | 31.93 | 31.13 | 26.57 | 37.68 | 31.27 |
Pension & Post-Retirement Benefits | 1.14 | 1.27 | 1.15 | 1.08 | - |
Long-Term Deferred Tax Liabilities | 11.91 | 34.11 | 32.73 | 32.87 | 32.6 |
Other Long-Term Liabilities | 0 | - | - | -0 | -0 |
Total Liabilities | 275.91 | 239.34 | 201.98 | 496.7 | 187.63 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 437.88 | 437.88 | 109.47 | 39.14 | 15.66 |
Additional Paid-In Capital | - | 47.4 | 91.19 | 22.79 | - |
Retained Earnings | - | 143 | 375.66 | 191.13 | 147.84 |
Comprehensive Income & Other | 460.61 | 0.08 | 0.08 | -0.09 | - |
Shareholders' Equity | 898.49 | 628.36 | 576.4 | 252.97 | 163.5 |
Total Liabilities & Equity | 1,174 | 867.7 | 778.37 | 749.66 | 351.13 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 50.2 | 41.77 | 31.54 | 50.82 | 33.77 |
Net Cash (Debt) | 9.57 | 79.41 | 68.27 | -11.09 | -30.87 |
Net Cash Growth | -87.95% | 16.33% | - | - | - |
Net Cash Per Share | 0.02 | 0.18 | 0.16 | -0.16 | -0.49 |
Filing Date Shares Outstanding | 429.05 | 437.88 | 438.39 | 438.39 | 62.63 |
Total Common Shares Outstanding | 429.05 | 437.88 | 438.39 | 438.39 | 62.63 |
Working Capital | 607.18 | 481.44 | 420.79 | 105.66 | 34.95 |
Book Value Per Share | 2.09 | 1.44 | 1.31 | 0.58 | 2.61 |
Tangible Book Value | 898.49 | 628.36 | 576.4 | 252.97 | 163.5 |
Tangible Book Value Per Share | 2.09 | 1.44 | 1.31 | 0.58 | 2.61 |
Land | - | 1.72 | 1.72 | 1.72 | 1.7 |
Buildings | - | 125.26 | 125.26 | 116.73 | 100.5 |
Machinery | - | 307.27 | 282.68 | 277.22 | 248.6 |
Construction In Progress | - | 19.45 | 16.62 | 16.62 | 16.62 |